334.60
전일 마감가:
$323.98
열려 있는:
$321.75
하루 거래량:
263.35K
Relative Volume:
0.72
시가총액:
$7.15B
수익:
-
순이익/손실:
$-518.67M
주가수익비율:
-13.32
EPS:
-25.12
순현금흐름:
$-438.32M
1주 성능:
+0.23%
1개월 성능:
-1.95%
6개월 성능:
+59.98%
1년 성능:
+36.85%
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
명칭
Madrigal Pharmaceuticals Inc
전화
404-380-9263
주소
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
MDGL을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
MDGL
Madrigal Pharmaceuticals Inc
|
334.60 | 7.15B | 0 | -518.67M | -438.32M | -25.12 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-02-28 | 업그레이드 | B. Riley Securities | Neutral → Buy |
2025-02-27 | 재확인 | H.C. Wainwright | Buy |
2024-06-28 | 개시 | Cantor Fitzgerald | Neutral |
2024-06-11 | 개시 | Wolfe Research | Outperform |
2024-04-22 | 개시 | BofA Securities | Underperform |
2024-03-15 | 업그레이드 | B. Riley Securities | Sell → Neutral |
2024-03-06 | 개시 | Citigroup | Buy |
2024-02-26 | 다운그레이드 | B. Riley Securities | Neutral → Sell |
2022-12-20 | 재확인 | Oppenheimer | Outperform |
2022-12-19 | 재확인 | H.C. Wainwright | Buy |
2022-12-19 | 재확인 | Piper Sandler | Overweight |
2022-12-19 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
2022-07-08 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
2021-10-07 | 개시 | Jefferies | Buy |
2021-08-06 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
2021-05-20 | 재개 | Goldman | Buy |
2020-11-24 | 재개 | Evercore ISI | Outperform |
2020-11-06 | 재확인 | H.C. Wainwright | Buy |
2020-07-31 | 개시 | Piper Sandler | Overweight |
2020-06-05 | 개시 | BMO Capital Markets | Market Perform |
2020-05-05 | 개시 | Chardan Capital Markets | Buy |
2020-01-30 | 개시 | Canaccord Genuity | Buy |
2020-01-09 | 업그레이드 | UBS | Neutral → Buy |
2019-11-07 | 재확인 | H.C. Wainwright | Buy |
2019-06-25 | 개시 | Stifel | Hold |
2019-06-10 | 업그레이드 | B. Riley FBR | Neutral → Buy |
2019-02-28 | 재확인 | H.C. Wainwright | Buy |
2019-02-22 | 개시 | SVB Leerink | Outperform |
2019-01-23 | 개시 | UBS | Neutral |
2018-12-14 | 개시 | Wolfe Research | Outperform |
2018-12-12 | 개시 | B. Riley FBR | Neutral |
2018-11-19 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
2018-11-16 | 업그레이드 | Evercore ISI | In-line → Outperform |
2018-09-04 | 개시 | Citigroup | Buy |
2018-08-06 | 다운그레이드 | Goldman | Buy → Neutral |
2018-06-28 | 개시 | Raymond James | Mkt Perform |
모두보기
Madrigal Pharmaceuticals Inc 주식(MDGL)의 최신 뉴스
Trend Tracker for (MDGL) - news.stocktradersdaily.com
Is Madrigal Pharmaceuticals (MDGL) The Most Expensive Stock Insiders Are Dumping In March? - Yahoo Finance
Madrigal (MDGL) Up 0.5% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Analysts Expect Breakeven For Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Before Long - simplywall.st
(MDGL) On The My Stocks Page - Stock Traders Daily
EU health regulator clears use of AI tool in fatty liver disease trials - Reuters
Madrigal Pharmaceuticals (MDGL): Among the Best Biotech Stocks to Buy According to Billionaires - Insider Monkey
15 Best Biotech Stocks to Buy According to Billionaires - Insider Monkey
Madrigal Pharmaceuticals Announces Changes to Board of Directors - MSN
Madrigal Pharmaceuticals SVP and CFO sells stock for $83,344 - Investing.com India
Madrigal Pharmaceuticals’ SWOT analysis: Rezdiffra success drives stock potential By Investing.com - Investing.com Australia
Madrigal Pharmaceuticals’ SWOT analysis: Rezdiffra success drives stock potential - Investing.com India
Madrigal Pharmaceuticals SVP and CFO sells stock for $83,344 By Investing.com - Investing.com Australia
Victory Capital Management Inc. Has $21.80 Million Stock Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - Defense World
Bank of New York Mellon Corp Lowers Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - Defense World
Madrigal Pharmaceuticals appoints new board member By Investing.com - Investing.com Australia
How the (MDGL) price action is used to our Advantage - Stock Traders Daily
Madrigal Pharmaceuticals Expands Board with New Appointment - TipRanks
Madrigal appoints Jacqualyn Fouse to its board -March 11, 2025 at 09:36 am EDT - Marketscreener.com
Madrigal Appoints Jacqualyn A. Fouse, Ph.D. To Board - citybiz
Madrigal Pharmaceuticals appoints new board member - Investing.com India
Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors - The Manila Times
Why Madrigal Pharmaceuticals (MDGL) Stock is Rising Today - GuruFocus.com
Robert E. Waltermire Sells 14,113 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stock - Defense World
Insider Sale at Madrigal Pharmaceuticals Inc (MDGL): Senior VP, - GuruFocus.com
Madrigal Pharmaceuticals Exec Cashes Out in Multi-Million Dollar Stock Sale! - TipRanks
Madrigal Pharmaceuticals’ senior VP sells $4.8 million in stock By Investing.com - Investing.com Canada
Madrigal Pharmaceuticals’ senior VP sells $4.8 million in stock - Investing.com India
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stock Holdings Reduced by Principal Financial Group Inc. - Defense World
Madrigal Pharmaceuticals CFO Mardi sells $637,247 in stock - Investing.com India
Madrigal Pharmaceuticals exec sells $418,488 in stock By Investing.com - Investing.com South Africa
Madrigal Pharmaceuticals exec sells $418,488 in stock - Investing.com
Madrigal Pharmaceuticals (NASDAQ:MDGL) Trading Down 6.8% on Insider Selling - Defense World
B. Riley Analysts Increase Earnings Estimates for MDGL - Defense World
Sanctuary Advisors LLC Acquires 62 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - Defense World
HC Wainwright Issues Negative Estimate for MDGL Earnings - Defense World
Madrigal Pharmaceuticals Reports Strong 2024 Growth Fueled by Rezdiffra Launch - MSN
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives $351.67 Consensus PT from Analysts - MarketBeat
New York State Common Retirement Fund Sells 5,630 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Citigroup Boosts Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target to $469.00 - Defense World
Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Up After Better-Than-Expected Earnings - MarketBeat
Madrigal Pharmaceuticals director Kenneth Bate sells $7.1m in stock By Investing.com - Investing.com Australia
(MDGL) Trading Report - Stock Traders Daily
Madrigal Pharmaceuticals director Kenneth Bate sells $7.1m in stock - Investing.com
Madrigal Pharmaceuticals Inc (MDGL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):